Double Bond Pharmaceutical International AB (DBPB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Double Bond Pharmaceutical International AB (DBPB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8149
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Double Bond Pharmaceutical International AB (DBP) is a pharmaceutical company that design, develop and commercialize therapies for cancer and autoimmune diseases. The company’s product pipeline includes SI-053 (Temodex), a novel therapy to treat malignant brain tumors; SA-033, SA-042, and SA-083 among others. It also designs medicinal products for treating patients suffering from diseases such as inflammation, asthma, diabetes, infections, autoimmune diseases and other life-threatening disorders. DBP utilizes BeloGal technology platform for direct targeting of a drug to the selected organs and tissues. The company works in collaboration with pharmaceutical companies to develop new medicinal products. DBP is headquartered in Uppsala, Stockholm, Sweden.

Double Bond Pharmaceutical International AB (DBPB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Double Bond Pharma Acquires Temodex from RI PCP 10
Partnerships 11
Double Bond Pharma Enters into Agreement with Romodanov Neurosurgery Institute 11
Double Bond Pharma Enters into Agreement with Uppsala University 12
Double Bond Pharmaceutical Expand Agreement with N.N. Alexandrov National Cancer 13
Double Bond Pharma Enters into Agreement with N.N. Alexandrov National Cancer Centre of Belarus 14
Double Bond Pharma Enters into Agreement with Research Institute of Bioorganic Chemistry 15
Licensing Agreements 16
Double Bond Pharma to Enter into Licensing Agreement for Temodex 16
Equity Offering 17
Double Bond Pharma to Raise Funds through Rights Offering of Shares 17
Double Bond Pharma to Raise USD0.3 Million in Private Placement of Shares 18
Double Bond Pharma Raises USD1 Million in Rights Offering of Shares 19
Double Bond Pharma Raises USD0.78 Million in Rights Offering of Shares 20
Double Bond Pharmaceutical International AB – Key Competitors 21
Double Bond Pharmaceutical International AB – Key Employees 22
Double Bond Pharmaceutical International AB – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Product News 24
Oct 05, 2018: Clinical trial of Inofer has started 24
Clinical Trials 25
Apr 18, 2017: The pre-clinical toxicological development of SA-033 is now completed 25
Other Significant Developments 26
May 29, 2018: Double Bond Pharma signs agreement for distribution of Helixor products 26
Apr 12, 2018: Double Bond Pharma signs agreement for distribution of Pharysol 27
Apr 03, 2018: Double Bond Pharma signs distribution agreement with Belmedpreparaty 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Key Facts 2
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Double Bond Pharmaceutical International AB, Deals By Therapy Area, 2012 to YTD 2018 8
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Double Bond Pharma Acquires Temodex from RI PCP 10
Double Bond Pharma Enters into Agreement with Romodanov Neurosurgery Institute 11
Double Bond Pharma Enters into Agreement with Uppsala University 12
Double Bond Pharmaceutical Expand Agreement with N.N. Alexandrov National Cancer 13
Double Bond Pharma Enters into Agreement with N.N. Alexandrov National Cancer Centre of Belarus 14
Double Bond Pharma Enters into Agreement with Research Institute of Bioorganic Chemistry 15
Double Bond Pharma to Enter into Licensing Agreement for Temodex 16
Double Bond Pharma to Raise Funds through Rights Offering of Shares 17
Double Bond Pharma to Raise USD0.3 Million in Private Placement of Shares 18
Double Bond Pharma Raises USD1 Million in Rights Offering of Shares 19
Double Bond Pharma Raises USD0.78 Million in Rights Offering of Shares 20
Double Bond Pharmaceutical International AB, Key Competitors 21
Double Bond Pharmaceutical International AB, Key Employees 22

List of Figures
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Double Bond Pharmaceutical International AB (DBPB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Concord New Energy Group Ltd (182):電力:M&Aディール及び事業提携情報
    Summary Concord New Energy Group Limited (Concord), formerly China WindPower Group Limited, is a clean and renewable energy company that carries out the construction, operation and maintenance of, and investment in, wind and solar power electricity generating facilities in China. Concord’s core busi …
  • NetApp Inc:企業の戦略・SWOT・財務情報
    NetApp Inc - Strategy, SWOT and Corporate Finance Report Summary NetApp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Bryte Insurance Company Ltd:企業の戦略・SWOT・財務情報
    Bryte Insurance Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Bryte Insurance Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University's researchers and students. The company’s products include exelon, doxil, cherry tomatoes and lo …
  • Verily Life Sciences LLC-医療機器分野:企業M&A・提携分析
    Summary Verily Life Sciences LLC (Verily), formerly known as Google Life Sciences LLC, a subsidiary of Alphabet Inc is a life sciences research and engineering organization which develops tools for prevention, detection, and management of diseases. The company develops tools for various projects, su …
  • Malaysian Pacific Industries Berhad (MPI):企業の財務・戦略的SWOT分析
    Malaysian Pacific Industries Berhad (MPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • RainDance Technologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary RainDance Technologies Inc (RDT), a subsidiary of Bio-Rad Laboratories Inc is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA; …
  • Sanara MedTech Inc (WNDM):企業の財務・戦略的SWOT分析
    Summary Sanara MedTech Inc (Sanara MedTech), formerly WNDM Medical Inc is a distributor of biotechnology products to hospitals, physicians, and clinics. The company offers its patented product CellerateRX in powder and gel forms, and hemaquell resorbable bone wax that controls bone bleeding. Its pro …
  • Mologic Ltd:企業の製品パイプライン分析2018
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company provides products such as bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit, amon …
  • Cosmo Pharmaceuticals NV (COPN):医療機器:M&Aディール及び事業提携情報
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • Green’s General Foods Pty Ltd:企業の戦略・SWOT・財務分析
    Green’s General Foods Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Green’s General Foods Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Pinsent Masons LLP:企業の戦略的SWOT分析
    Pinsent Masons LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Green Plains Inc (GPRE):企業の財務・戦略的SWOT分析
    Green Plains Inc (GPRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hainan Airlines Co Ltd:企業の戦略・SWOT・財務情報
    Hainan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hainan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Electromagnetic Geoservices ASA (EMGS):企業の財務・戦略的SWOT分析
    Summary Electromagnetic Geoservices ASA (EMGS) is an oil and gas service provider that explores workflow working with seismic, petrophysical and geologic data. The company gathers controlled source electromagnetic data and conduct modeling, integration, interpretation. Its technology finds applicati …
  • IBIDEN CO., LTD.:戦略・SWOT・企業財務分析
    IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Prudential Financial, Inc.:企業のM&A・事業提携・投資動向
    Prudential Financial, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prudential Financial, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Qurient Co Ltd (115180):製薬・医療:M&Aディール及び事業提携情報
    Summary Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs. The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatiti …
  • Prezzo Ltd:企業の戦略・SWOT・財務情報
    Prezzo Ltd - Strategy, SWOT and Corporate Finance Report Summary Prezzo Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • 3M India Limited (3MINDIA):企業の財務・戦略的SWOT分析
    3M India Limited (3MINDIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆